Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection

Carlos V. Paya, Paul E. Hermans, Thomas F. Smith, Jorge Rakela, Russell H. Wiesner, Ruud A.F. Krom, Vicente E. Torres, Sylvester Sterioff, Conrad J. Wilkowske

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Abstract

Twelve liver and 5 kidney transplant recipients with severe cytomegalovirus infection were treated with Ganciclovir (7.5 mg/kg/day, intravenously). Ten were evaluable (compatible clinical picture, organ involvement shown histopathologically or by culture, viremia, and absence of concomitant infection). All 17 patients were studied for adverse drug side effects. A total of 9 evaluable patients survived the infection; 1 died during treatment due to infection or drug toxicity. A death 19 days after completion of treatment was due to unrelated causes. Patients became afebrile after 2-9 days (mean, 5.3 days) of treatment. Liver function improved, pulmonary infiltrates cleared, and hypoxemia reversed during therapy. Viremia ceased during therapy in 9 patients; asymptomatic viruria persisted or recurred in 6 of 7 patients studied. No relapses occurred during follow-up (7—17 months; mean, 13 months). Transient neutropenia and thrombocytopenia occurred in 3 and 1 patients, respectively. Ganciclovir appears promising for treatment of severe CMV infection in patients with kidney or liver transplants.

Original languageEnglish (US)
Pages (from-to)229-234
Number of pages6
JournalTransplantation
Volume46
Issue number2
DOIs
StatePublished - Aug 1988

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection'. Together they form a unique fingerprint.

Cite this